EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia

Shunsuke Kamigaso, Yoshihiro Konno iD, Hirohiko Hikichi, Daiji Kambe iD, Yoko Mano, Yuichi Tokumaru, Haruyuki Mori, Hironori Yamasaki, Yukihiro Chino, Kenji Hachiuma, Akiko Mizuno-Yasuhira

Pharmacology Research & Perspectives · 2026

DOI: 10.1002/prp2.70217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Shunsuke Kamigaso und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan. Hauptthemen laut MEDLINE: Orexin Receptor Antagonists, Orexin Receptors, Sleep Initiation and Maintenance Disorders, Triazoles. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taisho Pharmaceutical, Taisho Toyama Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vornorexant is a novel dual orexin receptor antagonist (DORA) for the treatment of insomnia with a short elimination half‐life. Estimation of the human orexin receptor occupancy can provide insight into the duration of the sleep‐promoting effect of DORAs. Herein, we developed a pharmacokinetic‐receptor occupancy (PK/RO) model for OX 1 and OX 2 receptors in rats and estimated their receptor occupancy in humans based on the human plasma concentrations after oral administration of vornorexant. The estimated occupancy of the human OX 2 receptor, which is primarily involved in sleep induction, exceeded 70% at 30 min after dosing of therapeutic doses of 5 and 10 mg. The human OX 2 receptor occupancy at 6 h post‐dose of 5 and 10 mg was estimated to be approximately 50% and 60%, respectively, comparable to the occupancy necessary to exert sleep‐promoting effects in rats. Occupancy of the human OX 1 receptor by vornorexant was higher than that of the OX 2 receptor. The estimated human OX 1 and OX 2 receptor occupancy decreased with short half‐lives depending on the plasma concentration. These results suggest that vornorexant exerts rapid sleep‐promoting effects and maintains sleep for at least 6 h, and these estimations of the OX 2 receptor occupancy could support the clinical results. Vornorexant may have a favorable PK/RO profile for rapid sleep onset and sufficient sleep maintenance with minimal next‐day residual effects in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orexin Receptor AntagonistsOrexin ReceptorsSleep Initiation and Maintenance DisordersTriazolesModels, BiologicalAnimalsHumansRatsMaleHalf-LifeRats, Sprague-DawleyAdministration, Oral

Stichwörter der Autor:innen

TS‐142orexinpharmacokineticreceptor occupancyvornorexant

Substanzen

Orexin Receptor AntagonistsOrexin ReceptorsTriazolesHCRTR2 protein, humanHCRTR1 protein, human

Autor:innen und Institutionen

  • Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
  • Development Headquarters, Taisho Pharmaceutical Co., Ltd., Toshima, Japan.

ORCID-Profile: Yoshihiro Konno, Daiji Kambe

Förderung

  • Taisho Pharmaceutical
  • Taisho Toyama Pharmaceutical Company

Zitieren

APA

Kamigaso, S., Konno, Y., Hikichi, H., Kambe, D., Mano, Y., Tokumaru, Y., Mori, H., Yamasaki, H., Chino, Y., Hachiuma, K., & Mizuno-Yasuhira, A. (2026). Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70217

Vancouver

Kamigaso S, Konno Y, Hikichi H, Kambe D, Mano Y, Tokumaru Y, et al. Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70217

BibTeX
@article{Kamigaso2026,
  author = {Kamigaso, Shunsuke and Konno, Yoshihiro and Hikichi, Hirohiko and Kambe, Daiji and Mano, Yoko and Tokumaru, Yuichi and Mori, Haruyuki and Yamasaki, Hironori and Chino, Yukihiro and Hachiuma, Kenji and Mizuno-Yasuhira, Akiko},
  title = {Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics of Vornorexant, a Novel Dual Orexin 1/2 Receptor Antagonist for the Treatment of Insomnia},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  doi = {10.1002/prp2.70217}
}
Kostenlos starten →